Adtalem Global Education Inc. (ATGE) - Q1 FY2026 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for Adtalem Global Education Inc. for the period ended September 30, 2025, representing the first quarter of fiscal year 2026. Adtalem is a leading healthcare educator operating three reportable segments: Chamberlain University (nursing and health professions), Walden University (graduate and professional degrees), and Medical and Veterinary schools (AUC, RUSM, RUSVM). The company operates primarily in the U.S., Barbados, St. Kitts, and St. Maarten.
Key Financial Metrics
| Metric | Q1 FY2026 | Q1 FY2025 |
|---|---|---|
| Revenue | $462.3 million | $417.4 million |
| Operating Income | $85.5 million | $70.2 million |
| Net Income | $61.8 million | $46.2 million |
| Diluted EPS | $1.67 | $1.18 |
| Operating Cash Flow | $130.6 million | $89.6 million |
| Cash and Equivalents | $264.7 million | $221.2 million (beginning) |
| Long-Term Debt | $553.2 million | $552.7 million |
| Operating Margin | 18.5% | 16.8% |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenue increased 10.8% ($44.9 million) driven by growth across all segments. Walden led with a 17.6% increase, followed by Chamberlain (6.7%) and Medical/Veterinary (5.9%).
- Profitability: Net income rose 33.9% to $61.8 million. This was driven by revenue growth, a significant decrease in restructuring expenses ($0.3 million vs. $2.1 million prior year), and lower interest expense.
- Enrollment: Total student enrollment increased across the portfolio. Walden saw a 13.6% increase as of September 30, 2025. Chamberlain enrollment grew 4.5% in July and 2.2% in September 2025 sessions. Medical and Veterinary enrollment increased 2.4%.
- Cost Structure: Cost of educational services increased 7.9% due to labor costs supporting higher enrollment. Student services and administrative expenses rose 10.5%, partially due to $1.7 million in strategic advisory costs not present in the prior year.
Guidance, Outlook, Risks, and Unusual Items
- Legislative Impact (OBBBA): The "One Big Beautiful Bill Act" signed in July 2025 introduces substantial changes to federal student aid, including increased loan limits for professional programs but the eventual phase-out of Grad PLUS loans. It also introduces "Do No Harm" provisions that could impact Title IV eligibility based on graduate earnings. Management is analyzing the impact, noting potential adverse effects but also opportunities for new financing sources.
- Regulatory Status: Adtalem operates under provisional certification for Title IV programs due to a composite financial responsibility score below 1.5. The company maintains $179.0 million in letters of credit to satisfy ED requirements. No material adverse effect on operations is currently anticipated.
- Debt Management: On August 6, 2025, the company amended its credit agreement to increase the revolving facility to $500 million, extend maturity to 2030, and reduce pricing. On October 29, 2025 (post-period), the company prepaid $50 million on its Term Loan B.
- Share Repurchases: The company repurchased 56,817 shares for $7.6 million during the quarter. $142.4 million remains available under the current $150 million authorization.
- Legal Proceedings: The company is responding to Borrower Defense to Repayment (BDR) claims received from the Department of Education. As of September 10, 2025, institutions received over 14,000 claims, though none have been approved or resulted in recoupment notices to date.
Investor Verification Checklist
- Enrollment Sustainability: Verify if the 13.6% enrollment growth at Walden and steady growth at Chamberlain can be sustained given the competitive landscape and new federal loan restrictions.
- OBBBA Implementation: Monitor the Department of Education's rulemaking on the "Do No Harm" provisions and Grad PLUS phase-out to assess potential revenue headwinds.
- Provisional Certification: Track the company's financial responsibility composite score and any changes in ED oversight requirements or letter of credit obligations.
- BDR Exposure: Review future filings for updates on the status of the 14,000+ BDR claims and any potential recoupment liabilities.
- Debt Covenants: Confirm continued compliance with the Total Net Leverage Ratio covenant (max 3.25:1) as the company manages its debt load and interest rate environment.